Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $9.2252W HIGH $19.60
Volume
142.58 K
Value Traded
3.47 M
Short % Float
3.57%
-2.44%Week
-14.55%1 Month
-27.59%3 Month
-13.11%6 Month
-25.27%5 Year
-27.23%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
425.28 M
EPS (TTM)
-0.56
P/E Ratio
-
Ent. Value
432.59 M
Total Shares
34.33 M
Float Shares
26.80 M
Insiders
21.91%
Institutions
76.96%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
NPCE Catalyst Timeline
Dated clinical, regulatory and corporate events for Neuropace, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Neuropace, Inc.
2Total events
0Upcoming
0Tier-1 (high impact)
2026 to 2026Coverage
Past FDA Catalysts and PDUFA Decisions
How NPCE actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D32 / 100
Pipeline Score
$194M
Pipeline Value
Not rated
Valuation Signal
1
Drugs Scored
0.4x
rNPV / MCap
Top 63%
Micro Cap(rank 415 of 658)
Percentile Rank
Neuropace, Inc. faces pipeline headwinds (32/100), with $484M risk-adjusted pipeline value, led by RNS System in Epilepsy (Phase 2).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| RNS System UnknownNCT05339126 | Epilepsy | Phase 2 | ACTIVE NOT_RECRUITING | 24 | Dec 31, 2026 |
Clinical Trial Results
Readouts, endpoints and source filings for every NPCE program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| RNS System | drug-resistant focal epilepsy and idiopathic generalized epilepsy | 2026-04-27 | 82% median seizure reduction; 77% median reduction in GTC seizures; injury events declined by approximately 30%; use of a benzodiazepine as a rescue medication for a GTC seizure were 44% lowerRead More | NeuroPace Highlights Expanding Clinical Evidence Leadership with Published 3-Year Post-Approval Study (PAS) Results in Neurology and NAUTILUS Presentation at AAN 2026Read More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Morrell MarthaOfficer (CHIEF MEDICAL OFFICER) | Disposition | -358 52,385 held | $17.06 | 05/27/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in NPCE
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| SOLEUS CAPITAL MANAGEMENT, L.P. | 1.6 % (6.7 %) | 46.26 M | 2.91 M | 7.69% ( 207.91 K) |
NPCE Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How NPCE ranks across every disease it competes in
Competitive Position is a premium feature
See how NPCE ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialNPCE News
NPCENeuroPace to Participate in 2026 Cantor Global Healthcare Conference
NeuroPace, Inc. announced its participation in the 2026 Cantor Global Healthcare Conference. The management team will engage in a fireside chat on September 9 and conduct one-on-one meetings with investors. This event highlights NeuroPace's commitment to addressing epilepsy through innovative medical devices.
Read more →NPCENeuroPace to Participate in Wells Fargo 21st Annual Healthcare Conference
NeuroPace, Inc. will participate in the Wells Fargo 21st Annual Healthcare Conference. The management team is scheduled for a fireside chat on September 8 at 8:00am EDT and will hold one-on-one meetings with investors. This engagement highlights their commitment to transforming epilepsy treatment.
Read more →NPCENeuroPace Reports Second Quarter 2026 Financial Results and Raises 2026 Revenue Guidance
NeuroPace, Inc. reported its financial results for the second quarter of 2026, highlighting a total revenue of $22.8 million, which includes $22.5 million from the RNS System, marking a 21.3% increase from the same period in 2025. The company also raised its revenue guidance for the year, indicating positive growth prospects.
Read more →NPCE▼ -10.9%on this news
NeuroPace Receives FDA Guidance on PMA Supplement for Indication Expansion into Idiopathic Generalized Epilepsy
NeuroPace, Inc. has received FDA guidance regarding its Premarket Approval Panel Track Supplement. This supplement aims to expand the indication of the RNS® System to include patients suffering from antiseizure medication-resistant idiopathic generalized epilepsy (IGE). The communication from the FDA suggests a positive direction in the review process.
Read more →NPCENeuroPace to Highlight Expanding Role of Responsive Neuromodulation at the 2026 American Society for Stereotactic and Functional Neurosurgery (ASSFN) Meeting
NeuroPace is set to showcase its advancements in responsive neuromodulation at the upcoming 2026 ASSFN Meeting. The event will highlight the expanding applications of this technology in neurosurgery. Further details on the specific presentations or innovations to be discussed were not provided in the article.
Read more →NPCENeuroPace Announces FDA Approval of ECoG Assistant™, Advancing AI-Driven Epilepsy Care
NeuroPace has received FDA approval for its ECoG Assistant™, a device designed to enhance AI-driven care for epilepsy patients. This approval is a significant milestone for the company, indicating progress in innovative treatment options for epilepsy. The ECoG Assistant™ aims to improve patient outcomes through advanced technology.
Read more →NPCENeuroPace Reports First Quarter 2026 Financial Results and Raises 2026 Revenue Guidance
NeuroPace, Inc. has reported its first quarter 2026 financial results, highlighting total revenue of $22.1 million, marking a year-over-year growth of 20.1%. The company has raised its full-year revenue guidance for 2026 to between $99 million and $101 million, based on expectations of 21% to 23% growth in its core RNS revenue. However, NeuroPace reported a net loss of $6.7 million in the quarter despite these positive revenue figures, alongside an increase in operating expenses.
Read more →NPCENeuroPace to Report First Quarter 2026 Financial Results on May 12, 2026
NeuroPace, Inc. will report its financial results for Q1 2026 on May 12, 2026, after market close. A conference call will follow at 1:30 p.m. PT, accessible via webcast or telephone. NeuroPace specializes in innovative medical devices for epilepsy treatment, particularly through its RNS System, which provides personalized care.
Read more →NPCENeuroPace Highlights Expanding Clinical Evidence Leadership with Published 3-Year Post-Approval Study (PAS) Results in Neurology and NAUTILUS Presentation at AAN 2026
NeuroPace has published 3-year results from its RNS System Post-Approval Study, showing an 82% median seizure reduction in drug-resistant focal epilepsy. Additionally, the NAUTILUS trial presented 12- and 18-month data, revealing a 77% median reduction in generalized tonic-clonic seizures. These findings underscore NeuroPace's leadership in clinical evidence for epilepsy treatments.
Read more →NPCENeuroPace Reports Fourth Quarter and Full Year 2025 Financial Results and Reiterates 2026 Outlook
NeuroPace, Inc. reported strong financial results for Q4 and the full year 2025, highlighting a 24% growth in quarterly revenue to $26.6 million. The company reiterated its 2026 outlook, expecting 20% to 22% growth in RNS revenue. Efforts to secure regulatory approval for expanding indications and favorable reimbursement updates mark significant strategic progress. Nonetheless, the company still faces challenges, with ongoing negative adjusted EBITDA and rising operating expenses.
Read more →NPCENeuroPace Reports Preliminary Unaudited Results for the Fourth Quarter and Fiscal Year 2025 and Initial 2026 Outlook
NeuroPace, Inc. reported preliminary unaudited results for Q4 and FY 2025, showing significant revenue growth. The company anticipates continued growth in 2026, with expected revenues between $98 million and $100 million. However, it also announced the early termination of its partnership with DIXI Medical, which will affect future financial reporting.
Read more →NPCENeuroPace to Present at the 44th Annual J.P. Morgan Healthcare Conference
NeuroPace, Inc. will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026. The management team will discuss their innovative RNS System, designed to improve the treatment of epilepsy. The presentation will be available via live webcast and will include investor meetings.
Read more →NPCENeuroPace Files PMA Supplement to FDA Seeking Expanded RNS® System Indication for Idiopathic Generalized Epilepsy
NeuroPace, Inc. has submitted a PMA Supplement to the FDA to expand its RNS System indication for patients with drug-resistant idiopathic generalized epilepsy (IGE). This application is backed by promising results from the NAUTILUS trial, which reported a 77% median reduction in generalized tonic-clonic seizures. The RNS System has received Breakthrough Device Designation, highlighting its potential impact on treatment options for this patient group.
Read more →NPCENeuroPace to Highlight Life-Changing Outcomes and AI-Powered Confident Care at the 2025 American Epilepsy Society (AES) Annual Meeting
NeuroPace, Inc. will present its RNS System and AI platform at the 2025 AES Annual Meeting, highlighting new clinical data and AI advancements. The company aims to demonstrate how these innovations lead to significant seizure reductions and enhance physician confidence in treatment. Attendees can expect hands-on demonstrations and insights into the future of epilepsy care.
Read more →NPCENeuroPace Reports Third Quarter 2025 Financial Results and Increases 2025 Revenue Guidance
NeuroPace, Inc. reported its third-quarter 2025 financial results, highlighting a record revenue of $27.4 million, marking a 30% year-over-year growth. The company also increased its full-year revenue guidance to between $97 million and $98 million, with an impressive gross margin of 77.4%. Additionally, NeuroPace plans to submit a PMA supplement to the FDA for the RNS System by the end of 2025, focusing on the idiopathic generalized epilepsy indication. However, the company experienced a net loss of $3.5 million, raising concerns about future profitability amidst rising operational costs.
Read more →NPCENeuroPace Reports Second Quarter 2025 Financial Results and Increases 2025 Revenue Guidance
NeuroPace, Inc. reported a record revenue of $23.5 million for Q2 2025, marking a 22% increase year-over-year. The company has raised its full-year revenue guidance to between $94 million and $98 million. Despite these positive financial results, NeuroPace experienced an increase in operating and net losses. The company is on track to submit data for FDA indication expansion in the latter half of 2025.
Read more →NPCE▲ +5.6%on this news
NeuroPace Commends CMS for Maintaining FY25 Reimbursement Structure for Epilepsy with Neurostimulator Cases
NeuroPace, Inc. has praised the Centers for Medicare & Medicaid Services (CMS) for deciding not to change the reimbursement structure for its RNS System used in epilepsy treatment. This decision ensures that hospitals can continue providing care to Medicare beneficiaries without disruption. NeuroPace remains dedicated to collaborating with CMS on reimbursement improvements to enhance access for patients.
Read more →About Neuropace, Inc.
Headquarters455 N. BERNARDO AVENUE, MOUNTAIN VIEW, CA, 94043
BIOPHARMAWATCH ELITE PLUS
Trade the next NPCE catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime